Profils de résistance des souches urinaires de Proteus mirabilis de 1999 à 2005 au CHU de Nîmes

Bonnet, 1999, Diversity of TEM mutants in Proteus mirabilis, Antimicrob. Agents Chemother., 43, 2671, 10.1128/AAC.43.11.2671 Bouza, 2001, European perspective on nosocomial urinary tract infections II. Report on incidence, clinical characteristics and outcome (ESGNI-004 study). European Study Group on Nosocomial Infection, Clin. Microbiol. Infect., 7, 532, 10.1046/j.1198-743x.2001.00324.x Bret, 1996, Characterization of an inhibitor-resistant enzyme IRT-2 derived from TEM-2 betalactamase produced by Proteus mirabilis strains, J. Antimicrob. Chemother., 38, 183, 10.1093/jac/38.2.183 Cavallo, 2000, Med. Mal. Infect., 30, 714, 10.1016/S0399-077X(01)80005-6 Chanal, 2000, Prevalence of betalactamases among 1,072 clinical strains of Proteus mirabilis: a 2-year survey in a French hospital, Antimicrob. Agents Chemother., 44, 1930, 10.1128/AAC.44.7.1930-1935.2000 Chanal, 1996, Survey of prevalence of extended spectrum betalactamases among enterobacteriaceae, J. Antimicrob. Chemother., 38, 127, 10.1093/jac/38.1.127 de Champs, 2000, Clinical relevance of Proteus mirabilis in hospital patients: a two-year survey, J. Antimicrob. Chemother., 45, 537, 10.1093/jac/45.4.537 Delarbre, 2005, Antibiotic resistance: from the results of ONERBA's networks to good antibiotic use, Med. Mal. Infect., 35, S108, 10.1016/S0399-077X(05)81293-4 Farmer, 1999, Enterobacteriaceae: introduction and identification, 442 Hernandez, 2000, Trends in the susceptibilities of Proteus mirabilis isolates to quinolones, J. Antimicrob. Chemother., 45, 407, 10.1093/jac/45.3.407 Luzzaro, 2001, Properties of multidrug-resistant, ESBL-producing Proteus mirabilis isolates and possible role of [beta]-lactam/[beta]-lactamase inhibitor combinations, Int. J. Antimicrob. Agents, 17, 131, 10.1016/S0924-8579(00)00325-3 Mariotte, 1994, Extended-spectrum betalactamase in Proteus mirabilis, J. Antimicrob. Chemother., 33, 925, 10.1093/jac/33.5.925 Mathai, 2001, Epidemiology and frequency of resistance among pathogens causing urinary tract infections in 1,510 hospitalised patients: a report from the SENTRY Antimicrobial Surveillance Program (North America), Diagn. Microbiol. Infect. Dis., 40, 129, 10.1016/S0732-8893(01)00254-1 Nagano, 2003, Nosocomial outbreak of infections by Proteus mirabilis that produces extended-spectrum CTX-M-2 type betalactamase, J. Clin. Microbiol., 41, 5530, 10.1128/JCM.41.12.5530-5536.2003 Pagani, 2002, Emerging extended-spectrum betalactamases in Proteus mirabilis, J. Clin. Microbiol., 40, 1549, 10.1128/JCM.40.4.1549-1552.2002 Romaszko, 1995, Detection of betalactamases resistant to inhibitors (IRT) by the disk diffusion method, Pathol. Biol. (Paris), 43, 306 Saurina, 2000, Antimicrobial resistance in Enterobacteriaceae in Brooklyn, NY: epidemiology and relation to antibiotic usage patterns, J. Antimicrob. Chemother., 45, 895, 10.1093/jac/45.6.895 2006 Sirot, 1996, Detection of extended-spectrum plasmid-mediated betalactamases by disk diffusion, Clin. Microbiol. Infect., 2, S35, 10.1111/j.1469-0691.1996.tb00873.x Soussy, 2000, Antibiogram Committee of the French Microbiology Society. Report 2000–2001, Pathol. Biol. (Paris), 48, 832 Yong, 2006, The first detection of CTX-M-14 extended-spectrum betalactamase among diverse betalactamase producing Proteus mirabilis clinical isolates, Diagn. Microbiol. Infect. Dis, 54, 237, 10.1016/j.diagmicrobio.2005.09.013